Comprehensive Compliance Program and Declaration

INTRODUCTION

3D Dental Designs & Development (“3D” or the “Company”) is committed to the high standards of ethical conduct and corporate compliance. To that end, we have established a Comprehensive Compliance Program design to incorporate key elements set-out in the Compliance Program Guidance for Pharmaceuticals issued by the U.S. Department of Health and Human Services, Office of Inspector General (OIG). The OIG’s Compliance Program Guidance provides relevant information for healthcare company compliance programs.

The purpose of 3D’s Comprehensive Compliance Program is to prevent, detect, and remediate violations of Company standards and applicable law. We describe below the fundamental elements of the Company’s Comprehensive Compliance Program, which has been tailored to fit 3D’s size and resources, as well as the unique interactions that the Company has as a dsitributor of dental and medical products. As envisioned by the OIG’s Compliance Program Guidance, the Company endeavors to continually improve its Comprehensive Compliance Program in response to everevolving business activities, applicable laws, and associated compliance risks.

COMPREHENSIVE COMPLIANCE PROGRAM

Written Policies and Standards

We have adopted written policies and standards that provide guidance to our 3D Employees (“3DE’s”) in their dealing with health care professionals, customers, suppliers, government entities, society at large, other employees, and other third parties. They also address the methods and means by which the Comprehensive Compliance Program is administered and enforced.

The cornerstone of our written standards is 3D’s Worldwide Business Standards, which is supplemented by policies and procedures, guidelines, directives and other communications that address applicable federal, state and foreign laws and industry standards relating to the marketing, promotion, distribution and sale of the Company’s products and services. 3D has also adopted a Marketing Code of Conduct Policy governing interactions with healthcare professionals.

In addition, in accordance with California law, 3D has set an annual dollar limi on items or activities of value (define in the law) that the Company provides to each inidividual California health professional ($2500 per covered recipient per year).

Leadership and Oversight

The Company’s Chief Executive Officer has appointed a Chief Ethics and Compliance Officer (“CECO”) who has overall responsibility for managing and overseeing the Compliance Program, is empowered with appropriate authority to exercise independent judgement, and has free and unencumbered access to senior management and the Board of Directors.

In order to assist the CECO in implementing, executing and monitoring the Comprehensive Compliance Program, the Company’s Chief Executive Officer has also appointed a Compliance Committee comprised of members of senior management. This Committee assists the CECO, as needed, in implementing the Compliance Program.

The Compliance Committee and/or CECO periodically reports to the Board of Directors (or a committee thereof) concerning the Comprehensive Compliance Program.

Training and Education

3D is committed to effectively communicating our standards and procedures to Company personnel. Our training activities include a combination of in-person presentations, online web modules, printed materials, and individualized sessions. 3D periodically reviews and updates its training programs and identifies additional areas of training on an “as needed” basis.

Communication and Helpline Reporting

3D encourages open and candid discussion between management and 3DEs regarding any compliance concerns. Our goal is that all 3DEs, when seeking answers to questions or reporting potential instances of misconduct, should know to whom to turn for a meaningful response and should be able to do so without fear of retaliation. 3DEs are encouraged to report their concerns to a) their manager, b) the Compliance Helpline, c) the Ethics and Compliance Department, d) any member of the Compliance Committee; (e) the General Counsel’s office or local Legal department if outside the U.S., (f) Internal Audit, (g) their local Human Resources contact, or (h) other senior Company official. 3D maintains a Compliance Helpline with a toll-free number (by country) to receive reports from 3DEs and others in connection with alleged violations of our standards or applicable laws by any 3DE, contractor, subcontractor, supplier, customer, or other person. Reports to the Compliance Helpline may be made anonymously, if desired.

Risk Assessment, Auditing and Monitoring

3D periodically assesses the risk of misconduct and takes reasonable measures to design, implement, or modify each element of the compliance program, as required. The Ethics and Compliance team conduct a risk assessment using a risk-baseed approach. 3D conducts compliance audits periodically to evaluate adherence to the Company’s standards. The Company also monitors for new and emerging risk areas on an ongoing basis. The nature of our reviews, as well as the extent and frequency of our compliance monitoring and auditing, varies according to a variety of factors, including new regulatory requirements, changes in business practices, and other considerations.

Enforcement and Disciplinary Measures

We conduct fair, diligent and timely investigations of reports of potential non-compliance that are brought to the Company’s attention. 3D takes disciplinary actions, where appropriate, in response to confirmed violations of the Company’s standards, and strives to ensure consistent application of the Company’s standards.

Responses to Detected Problems and Corrective Actions

An effective compliance program increases the likelihood of preventing and detecting unlawful and unethical behavior. However, even an effective compliance program may not prevent all violations. Accordingly, the Company’s Comprehensive Compliance Program requires a prompt response to potential violations of the law, standards or Company policy. Actions in response to detected problems, and to prevent future violations, may include improving policies or procedures, training, communication and monitoring or discplinary action.

DECLARATION OF COMPLIANCE WITH CALIFORNIA HEALTH AND SAFETY CODE

• §§119400-119402

3D has adopted a Comprehensive Compliance Program guided by OIG’s Compliance Program Guidance for Pharmaceutical and industry standards. We tailored our Comprehensive Compliance Program to the nature of our business as a distributor of dental and medical products.

The California law makes reference to compliance with the PhRMA code on Interatons with Healthcare Professionals (PhRMA Code), which is an industry standard that applies to pharmaceuticals and does not reflect the unique nature of distributor activities. We have, accordingly, not adopted the PhRMA Code, but instead have adopted a marketing code of conduct intended to help ensure our compliance with the applicable laws and regulations and consistent with industry standards for distributors.

We believe that 3D has developed a Comprehensive Compliance Program that meets the compliance goals set forth by California Health and Safety Code sections 119400 through
119402. To our knowledge, we are, in all material respects, in compliance with our Comprehensive Compliance Program and the requirements of California Health and Safety Code sections 119400 through 119402, as we interpret and apply the requirements to the nature of our business. Although we are not making a representation that every employee and agent will always fully comply with our standards and rules, our Comprehensive Compliance Program is reasonably designed to prevent and detect violations. We are committed to monitoring our conduct and taking appropriate action to discipline Company personnel who violate our standards. Copies of this declaration and the above description of our Comprehensive Compliance program may be obtained by calling 3D Compliance Helpline: 877-605-8061 (for the United States and Canada) or by visiting the company website.

Dated: June 18, 2025